2. Academic Validation
  3. Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu7 Negative Allosteric Modulator (NAM) in Vivo Tool Compound: N-(2-(1 H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962)

Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu7 Negative Allosteric Modulator (NAM) in Vivo Tool Compound: N-(2-(1 H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962)

  • J Med Chem. 2019 Feb 14;62(3):1690-1695. doi: 10.1021/acs.jmedchem.8b01810.
Carson W Reed,  Samantha E Yohn,  Jordan P Washecheck,  Hanna F Roenfanz,  Marc C Quitalig,  Vincent B Luscombe,  Matthew T Jenkins,  Alice L Rodriguez,  Darren W Engers,  Anna L Blobaum,  P Jeffrey Conn 1,  Colleen M Niswender 1,  Craig W Lindsley
Affiliations

Affiliation

  • 1 Vanderbilt Kennedy Center , Vanderbilt University School of Medicine , Nashville , Tennessee 37232 , United States.
PMID: 30608678 DOI: 10.1021/acs.jmedchem.8b01810
Abstract

Herein, we report the discovery of a new, orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 (mGlu7) negative allosteric modulator (NAM) that achieves exposure in cerebral spinal fluid (CSF) 2.5× above the in vitro IC50 at minimum effective doses (MEDs) of 3 mg/kg in preclinical anxiety models.

Figures
Products